{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:26:16Z","timestamp":1787293576370,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Anemia, inflammation and iron deficiency are linked to Fibroblast growth factor 23 (FGF23). Aim of this study was to explore the dynamics of FGF23 in Hereditary Hemochromatosis type-I (HH1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-six consecutive patients with genetically confirmed and uncomplicated HH1 and nineteen healthy age-matched voluntary blood donors (CTR) were enrolled for the study. Intact (iFGF23) and C-terminal (cFGF23) FGF23 and iron status markers were evaluated at baseline (T0) and seven days (T7) after phlebotomy\/voluntary blood donation (VBD). Bone mineral density (BMD) and vertebral fracture assessment (VFA) were also evaluated at T0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cross-sectional and longitudinal analyses failed to reveal significant differences in iFGF23 in both HH1 (T0: 54.27 \u00b1 14.42 pg\/mL; T7: 54.70 \u00b1 15.48 pg\/mL) and CTR (T0: 52.77 \u00b1 17.63 pg\/mL; T7: 53.27 \u00b1 15.88 pg\/mL) groups. Absence of significant difference was also observed for cFGF23 at baseline between the two groups (HH1, T0: 0.98 \u00b1 0.39 pmol\/L; CTR, T0: 1.18 \u00b1 0.91 pmol\/L) but not at T7 when the values (HH1, T7: 01.20 \u00b1 0.89; CTR, T7: 1.84 \u00b1 1.11 pmol\/L) were significantly increased in CTR compared to T0 (p = 0.0003) and to HH1 (p = 0.0240). After phlebotomy\/VBD, in both HH1 and CTR groups, serum levels of phosphate were unchanged from baseline while serum iron, ferritin and transferrin saturation and erythrocyte-related parameters (red blood cells, hemoglobin and hematocrit) were significantly reduced (all p \u2009&lt;\u2009 0.0001). Serum iron, ferritin, and transferrin saturation were significantly higher in HH1 than in CTR (p = 0.0002 for serum iron and p \u2009&lt;\u2009 0.0001 for both ferritin and transferrin saturation) at T7. In the CTR group, these parameters showed a trend toward iron deficiency whereas in HH1 they remained near the upper limit of the normal range, suggesting a persistent mild iron overload. Correlation and regression analyses did not show significant associations between circulating FGF23 (both iFGF23 and cFGF23) and iron status markers. BMD and VFA were not significantly different between HH1 and CTR. Furthermore, BMD and Trabecular Bone Score values were not associated with circulating FGF23 levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pilot study indicates that the serum levels of iFGF23 and cFGF23 and skeletal health evaluated through BMD and VFA do not differ between patients with uncomplicated HH1 and healthy subjects at baseline. The absence of changes in the serum levels of iFGF23 and cFGF23 in HH1 patients with uncomplicated HH1 after phlebotomy may reflect the persistence of iron overload which could counteract the physiological hypoxia-driven stimulation of FGF23 production and cleavage observed in healthy subjects after VBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-026-02893-5","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:41:16Z","timestamp":1779792076000},"page":"2439-2448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the dynamics of FGF23 in patients with Hereditary Hemochromatosis type I following iron depletive treatment: a pilot study"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9310","authenticated-orcid":false,"given":"Luciano","family":"Colangelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Terracina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Ferrazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Panzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Diacinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Nieddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Arienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Occhiuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Trasarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Angeloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Corsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2893_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","volume":"16","author":"D Edmonston","year":"2020","unstructured":"Edmonston D, Wolf M (2020) FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol 16:7\u201319. https:\/\/doi.org\/10.1038\/s41581-019-0189-5","journal-title":"Nat Rev Nephrol"},{"key":"2893_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1210\/endrev\/bnac026","volume":"44","author":"S Minisola","year":"2023","unstructured":"Minisola S, Fukumoto S, Xia W, Corsi A, Colangelo L, Scillitani A, Pepe J, Cipriani C, Thakker RV (2023) Tumor-induced Osteomalacia: A Comprehensive Review. Endocr Rev 44:323\u2013353. https:\/\/doi.org\/10.1210\/endrev\/bnac026","journal-title":"Endocr Rev"},{"key":"2893_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bone.2015.12.055","volume":"84","author":"H Yamamoto","year":"2016","unstructured":"Yamamoto H, Ramos-Molina B, Lick AN, Prideaux M, Albornoz V, Bonewald L, Lindberg I (2016) Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition. Bone 84:120\u2013130. https:\/\/doi.org\/10.1016\/j.bone.2015.12.055","journal-title":"Bone"},{"key":"2893_CR4","doi-asserted-by":"publisher","first-page":"8821292","DOI":"10.1155\/2021\/8821292","volume":"2021","author":"A Kurpas","year":"2021","unstructured":"Kurpas A, Supel K, Idzikowska K, Zielinska M (2021) FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease. Dis Markers 2021:8821292. https:\/\/doi.org\/10.1155\/2021\/8821292","journal-title":"Dis Markers"},{"key":"2893_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00223-022-00987-9","volume":"112","author":"AC Heijboer","year":"2023","unstructured":"Heijboer AC, Cavalier E (2023) The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations. Calcif Tissue Int 112:258\u2013270. https:\/\/doi.org\/10.1007\/s00223-022-00987-9","journal-title":"Calcif Tissue Int"},{"key":"2893_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fphys.2019.00304","volume":"10","author":"AJ van Vuren","year":"2019","unstructured":"van Vuren AJ, Gaillard C, Eisenga MF, van Wijk R, van Beers EJ (2019) The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research. Front Physiol 10:304. https:\/\/doi.org\/10.3389\/fphys.2019.00304","journal-title":"Front Physiol"},{"key":"2893_CR7","doi-asserted-by":"publisher","unstructured":"Martinez-Heredia L, Canelo-Moreno JM, Garcia-Fontana B, Munoz-Torres M (2024) Non-Classical Effects of FGF23: Molecular and Clinical Features. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25094875","DOI":"10.3390\/ijms25094875"},{"key":"2893_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ki.2015.290","volume":"89","author":"V David","year":"2016","unstructured":"David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, Wolf M (2016) Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89:135\u2013146. https:\/\/doi.org\/10.1038\/ki.2015.290","journal-title":"Kidney Int"},{"key":"2893_CR9","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1210\/jc.2011-1239","volume":"96","author":"EA Imel","year":"2011","unstructured":"Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:3541\u20133549. https:\/\/doi.org\/10.1210\/jc.2011-1239","journal-title":"J Clin Endocrinol Metab"},{"key":"2893_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/jbmr.2049","volume":"29","author":"EL Clinkenbeard","year":"2014","unstructured":"Clinkenbeard EL, Farrow EG, Summers LJ, Cass TA, Roberts JL, Bayt CA, Lahm T, Albrecht M, Allen MR, Peacock M, White KE (2014) Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Min Res 29:361\u2013369. https:\/\/doi.org\/10.1002\/jbmr.2049","journal-title":"J Bone Min Res"},{"key":"2893_CR11","doi-asserted-by":"publisher","first-page":"F1369","DOI":"10.1152\/ajprenal.00281.2016","volume":"311","author":"MR Hanudel","year":"2016","unstructured":"Hanudel MR, Chua K, Rappaport M, Gabayan V, Valore E, Goltzman D, Ganz T, Nemeth E, Salusky IB (2016) Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Ren Physiol 311:F1369\u2013F1377. https:\/\/doi.org\/10.1152\/ajprenal.00281.2016","journal-title":"Am J Physiol Ren Physiol"},{"key":"2893_CR12","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Min Res 28:1793\u20131803. https:\/\/doi.org\/10.1002\/jbmr.1923","journal-title":"J Bone Min Res"},{"key":"2893_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bone.2016.03.005","volume":"86","author":"EA Imel","year":"2016","unstructured":"Imel EA, Liu Z, McQueen AK, Acton D, Acton A, Padgett LR, Peacock M, Econs MJ (2016) Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women. Bone 86:98\u2013105. https:\/\/doi.org\/10.1016\/j.bone.2016.03.005","journal-title":"Bone"},{"key":"2893_CR14","doi-asserted-by":"publisher","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","volume":"108","author":"EG Farrow","year":"2011","unstructured":"Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 108:E1146\u20131155. https:\/\/doi.org\/10.1073\/pnas.1110905108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2893_CR15","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1074\/jbc.M413248200","volume":"280","author":"S McMahon","year":"2005","unstructured":"McMahon S, Grondin F, McDonald PP, Richard DE, Dubois CM (2005) Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem 280:6561\u20136569. https:\/\/doi.org\/10.1074\/jbc.M413248200","journal-title":"J Biol Chem"},{"key":"2893_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood-2007-07-100677","volume":"111","author":"L Silvestri","year":"2008","unstructured":"Silvestri L, Pagani A, Camaschella C (2008) Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 111:924\u2013931. https:\/\/doi.org\/10.1182\/blood-2007-07-100677","journal-title":"Blood"},{"key":"2893_CR17","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/ndt\/gfy189","volume":"34","author":"MR Hanudel","year":"2019","unstructured":"Hanudel MR, Eisenga MF, Rappaport M, Chua K, Qiao B, Jung G, Gabayan V, Gales B, Ramos G, de Jong MA, van Zanden JJ, de Borst MH, Bakker SJL, Nemeth E, Salusky IB, Gaillard C, Ganz T (2019) Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transpl 34:2057\u20132065. https:\/\/doi.org\/10.1093\/ndt\/gfy189","journal-title":"Nephrol Dial Transpl"},{"key":"2893_CR18","doi-asserted-by":"publisher","unstructured":"Gobbo A, Longo F, Cattaneo CA, Verrienti M, Marzi G, Chamekh F, Culcasi M, Cossu A, Zatelli MC, Ambrosio MR (2025) iFGF23 Plasma Levels in Transfusion-Dependent beta-Thalassemia: Insights into Bone and Iron Metabolism. J Clin Med 14. https:\/\/doi.org\/10.3390\/jcm14061834","DOI":"10.3390\/jcm14061834"},{"key":"2893_CR19","doi-asserted-by":"publisher","first-page":"18016","DOI":"10.1038\/nrdp.2018.16","volume":"4","author":"P Brissot","year":"2018","unstructured":"Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loreal O (2018) Haemochromatosis Nat Rev Dis Primers 4:18016. https:\/\/doi.org\/10.1038\/nrdp.2018.16","journal-title":"Haemochromatosis Nat Rev Dis Primers"},{"key":"2893_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jhep.2022.03.033","volume":"77","author":"European Association for the Study of the L","year":"2022","unstructured":"European Association for the Study of the L (2022) EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol 77:479\u2013502. https:\/\/doi.org\/10.1016\/j.jhep.2022.03.033","journal-title":"J Hepatol"},{"key":"2893_CR21","first-page":"1809","volume":"24","author":"L Sinigaglia","year":"1997","unstructured":"Sinigaglia L, Fargion S, Fracanzani AL, Binelli L, Battafarano N, Varenna M, Piperno A, Fiorelli G (1997) Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol 24:1809\u20131813","journal-title":"J Rheumatol"},{"key":"2893_CR22","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s00198-005-1934-0","volume":"16","author":"P Guggenbuhl","year":"2005","unstructured":"Guggenbuhl P, Deugnier Y, Boisdet JF, Rolland Y, Perdriger A, Pawlotsky Y, Chales G (2005) Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 16:1809\u20131814. https:\/\/doi.org\/10.1007\/s00198-005-1934-0","journal-title":"Osteoporos Int"},{"key":"2893_CR23","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00198-008-0701-4","volume":"20","author":"L Valenti","year":"2009","unstructured":"Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S, Sinigaglia L (2009) Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 20:549\u2013555. https:\/\/doi.org\/10.1007\/s00198-008-0701-4","journal-title":"Osteoporos Int"},{"key":"2893_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00223-020-00658-7","volume":"106","author":"NM Jandl","year":"2020","unstructured":"Jandl NM, Rolvien T, Schmidt T, Mussawy H, Nielsen P, Oheim R, Amling M, Barvencik F (2020) Impaired Bone Microarchitecture in Patients with Hereditary Hemochromatosis and Skeletal Complications. Calcif Tissue Int 106:465\u2013475. https:\/\/doi.org\/10.1007\/s00223-020-00658-7","journal-title":"Calcif Tissue Int"},{"key":"2893_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.tem.2022.06.004","volume":"33","author":"U Baschant","year":"2022","unstructured":"Baschant U, Altamura S, Steele-Perkins P, Muckenthaler MU, Spasic MV, Hofbauer LC, Steinbicker AU, Rauner M (2022) Iron effects versus metabolic alterations in hereditary hemochromatosis driven bone loss. Trends Endocrinol Metab 33:652\u2013663. https:\/\/doi.org\/10.1016\/j.tem.2022.06.004","journal-title":"Trends Endocrinol Metab"},{"key":"2893_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/1096-8652(200011)65:3<223::aid-ajh8>3.0.co;2-9","volume":"65","author":"JC Barton","year":"2000","unstructured":"Barton JC, Bottomley SS (2000) Iron deficiency due to excessive therapeutic phlebotomy in hemochromatosis. Am J Hematol 65:223\u2013226. https:\/\/doi.org\/10.1002\/1096-8652(200011)65:3%3C223::aid-ajh8%3E3.0.co;2-9","journal-title":"Am J Hematol"},{"key":"2893_CR27","doi-asserted-by":"publisher","first-page":"F132","DOI":"10.1152\/ajprenal.00081.2017","volume":"314","author":"S Rabadi","year":"2018","unstructured":"Rabadi S, Udo I, Leaf DE, Waikar SS, Christov M (2018) Acute blood loss stimulates fibroblast growth factor 23 production. Am J Physiol Ren Physiol 314:F132\u2013F139. https:\/\/doi.org\/10.1152\/ajprenal.00081.2017","journal-title":"Am J Physiol Ren Physiol"},{"key":"2893_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.bone.2019.05.029","volume":"125","author":"F Ferrone","year":"2019","unstructured":"Ferrone F, Pepe J, Danese VC, Fassino V, Cecchetti V, De Lucia F, Biamonte F, Colangelo L, Ferrazza G, Panzini E, Scillitani A, Nieddu L, Blocki F, Rao SD, Minisola S, Cipriani C (2019) The relative influence of serum ionized calcium and 25-hydroxyvitamin D in regulating PTH secretion in healthy subjects. Bone 125:200\u2013206. https:\/\/doi.org\/10.1016\/j.bone.2019.05.029","journal-title":"Bone"},{"key":"2893_CR29","doi-asserted-by":"publisher","first-page":"115608","DOI":"10.1016\/j.bone.2020.115608","volume":"143","author":"D Diacinti","year":"2021","unstructured":"Diacinti D, Pisani D, Cipriani C, Celli M, Zambrano A, Diacinti D, Kripa E, Iannacone A, Colangelo L, Nieddu L, Pepe J, Minisola S (2021) Vertebral fracture assessment (VFA) for monitoring vertebral reshaping in children and adolescents with osteogenesis imperfecta treated with intravenous neridronate. Bone 143:115608. https:\/\/doi.org\/10.1016\/j.bone.2020.115608","journal-title":"Bone"},{"key":"2893_CR30","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Min Res 8:1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Min Res"},{"key":"2893_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s40610-019-0110-9","volume":"5","author":"JA Wheeler","year":"2019","unstructured":"Wheeler JA, Clinkenbeard EL (2019) Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF. Curr Mol Biol Rep 5:8\u201317. https:\/\/doi.org\/10.1007\/s40610-019-0110-9","journal-title":"Curr Mol Biol Rep"},{"key":"2893_CR32","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2147\/JBM.S375945","volume":"13","author":"E Mantadakis","year":"2022","unstructured":"Mantadakis E, Panagopoulou P, Kontekaki E, Bezirgiannidou Z, Martinis G (2022) Iron Deficiency and Blood Donation: Links, Risks and Management. J Blood Med 13:775\u2013786. https:\/\/doi.org\/10.2147\/JBM.S375945","journal-title":"J Blood Med"},{"key":"2893_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3345\/cep.2023.01732","volume":"68","author":"HL Jung","year":"2025","unstructured":"Jung HL (2025) Absolute versus functional iron deficiency. Clin Exp Pediatr 68:138\u2013140. https:\/\/doi.org\/10.3345\/cep.2023.01732","journal-title":"Clin Exp Pediatr"},{"key":"2893_CR34","doi-asserted-by":"publisher","first-page":"e0186979","DOI":"10.1371\/journal.pone.0186979","volume":"12","author":"I Flamme","year":"2017","unstructured":"Flamme I, Ellinghaus P, Urrego D, Kruger T (2017) FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. PLoS ONE 12:e0186979. https:\/\/doi.org\/10.1371\/journal.pone.0186979","journal-title":"PLoS ONE"},{"key":"2893_CR35","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00424-018-2171-7","volume":"470","author":"A Daryadel","year":"2018","unstructured":"Daryadel A, Bettoni C, Haider T, Imenez Silva PH, Schnitzbauer U, Pastor-Arroyo EM, Wenger RH, Gassmann M, Wagner CA (2018) Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men. Pflugers Arch 470:1569\u20131582. https:\/\/doi.org\/10.1007\/s00424-018-2171-7","journal-title":"Pflugers Arch"},{"key":"2893_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/MOH.0000000000000733","volume":"29","author":"BR Spencer","year":"2022","unstructured":"Spencer BR, Mast AE (2022) Iron status of blood donors. Curr Opin Hematol 29:310\u2013316. https:\/\/doi.org\/10.1097\/MOH.0000000000000733","journal-title":"Curr Opin Hematol"},{"key":"2893_CR37","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.kint.2018.06.028","volume":"94","author":"N Suzuki","year":"2018","unstructured":"Suzuki N, Matsuo-Tezuka Y, Sasaki Y, Sato K, Miyauchi K, Kato K, Saito S, Shimonaka Y, Hirata M, Yamamoto M (2018) Iron attenuates erythropoietin production by decreasing hypoxia-inducible transcription factor 2alpha concentrations in renal interstitial fibroblasts. Kidney Int 94:900\u2013911. https:\/\/doi.org\/10.1016\/j.kint.2018.06.028","journal-title":"Kidney Int"},{"key":"2893_CR38","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1053\/j.gastro.2013.12.031","volume":"146","author":"YM Shah","year":"2014","unstructured":"Shah YM, Xie L (2014) Hypoxia-inducible factors link iron homeostasis and erythropoiesis. Gastroenterology 146:630\u2013642. https:\/\/doi.org\/10.1053\/j.gastro.2013.12.031","journal-title":"Gastroenterology"},{"key":"2893_CR39","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.kint.2018.07.027","volume":"94","author":"T Ganz","year":"2018","unstructured":"Ganz T (2018) Erythropoietin and iron-a conflicted alliance? Kidney Int 94:851\u2013853. https:\/\/doi.org\/10.1016\/j.kint.2018.07.027","journal-title":"Kidney Int"},{"key":"2893_CR40","doi-asserted-by":"publisher","first-page":"116645","DOI":"10.1016\/j.ejmech.2024.116645","volume":"275","author":"B Cheng","year":"2024","unstructured":"Cheng B, Ma X, Zhou Y, Liu J, Fei X, Pan W, Peng X, Wang W, Chen J (2024) Recent progress in the development of hypoxia-inducible factor 2alpha (HIF-2alpha) modulators: Inhibitors, agonists, and degraders (2009\u20132024). Eur J Med Chem 275:116645. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116645","journal-title":"Eur J Med Chem"},{"key":"2893_CR41","doi-asserted-by":"publisher","unstructured":"Bakleh MZ, Al Haj Zen A (2025) The Distinct Role of HIF-1alpha and HIF-2alpha in Hypoxia and Angiogenesis. Cells 14. https:\/\/doi.org\/10.3390\/cells14090673","DOI":"10.3390\/cells14090673"},{"key":"2893_CR42","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/jor.22133","volume":"30","author":"P Jia","year":"2012","unstructured":"Jia P, Xu YJ, Zhang ZL, Li K, Li B, Zhang W, Yang H (2012) Ferric ion could facilitate osteoclast differentiation and bone resorption through the production of reactive oxygen species. J Orthop Res 30:1843\u20131852. https:\/\/doi.org\/10.1002\/jor.22133","journal-title":"J Orthop Res"},{"key":"2893_CR43","doi-asserted-by":"publisher","first-page":"e0207441","DOI":"10.1371\/journal.pone.0207441","volume":"13","author":"M Simao","year":"2018","unstructured":"Simao M, Camacho A, Ostertag A, Cohen-Solal M, Pinto IJ, Porto G, Hang Korng E, Cancela ML (2018) Iron-enriched diet contributes to early onset of osteoporotic phenotype in a mouse model of hereditary hemochromatosis. PLoS ONE 13:e0207441. https:\/\/","journal-title":"PLoS ONE"},{"key":"2893_CR44","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00223-018-0429-x","volume":"103","author":"L Colangelo","year":"2018","unstructured":"Colangelo L, Cipriani C, Pepe J, Corsi A, Sonato C, Follacchio G, Cilli M, Gianni W, Ferrone F, Moreschini O, Fitzpatrick LA, Minisola S (2018) A Challenging Case of Tumor-Induced Osteomalacia: Pathophysiological and Clinical Implications. Calcif Tissue Int 103:465\u2013468. https:\/\/doi.org\/10.1007\/s00223-018-0429-x","journal-title":"Calcif Tissue Int"},{"key":"2893_CR45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00223-025-01394-6","volume":"116","author":"L Colangelo","year":"2025","unstructured":"Colangelo L, Di Ciommo FR, Palmisano B, Scrivo R, Della Monaca M, Pepe J, Cipriani C, Alessandri C, Valentini V, Riminucci M, Minisola S, Conti F, Corsi A (2025) Exploring the Role of FGF7 in Tumor-Induced Osteomalacia. Clinic-Pathologic Analysis in a Patient with a Sino-Nasal Phosphaturic Mesenchymal Tumor. Calcif Tissue Int 116:82. https:\/\/doi.org\/10.1007\/s00223-025-01394-6","journal-title":"Calcif Tissue Int"},{"key":"2893_CR46","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/ibd\/izad010","volume":"29","author":"R Loveikyte","year":"2023","unstructured":"Loveikyte R, Bourgonje AR, van der Reijden JJ, Bulthuis MLC, Hawinkels L, Visschedijk MC, Festen EAM, van Dullemen HM, Weersma RK, van Goor H, van der Meulen-de Jong AE, Dijkstra G (2023) Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab. Inflamm Bowel Dis 29:1272\u20131284. https:\/\/doi.org\/10.1093\/ibd\/izad010","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02893-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02893-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02893-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:08:47Z","timestamp":1787292527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-02893-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2893"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02893-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have read and agreed to publish the manuscript.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of \u201cSapienza\u201d University of Rome (protocol number 0374\/2022).","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Salvatore Minisola has served as a speaker for Abiogen, Bruno Farmaceutici, Diasorin, Kyowa Kirin, and UCB; and has also served on the advisory board of Eli Lilly, Kyowa Kirin, and UCB. Luciano Colangelo, Sergio Terracina, Chiara Sonato, Viviana De Martino, Giancarlo Ferrazza, Enrico Panzini, Daniele Diacinti, Luciano Nieddu, Francesca Arienzo, Marco Occhiuto, Cristiana Cipriani, Stefania Trasarti, Antonio Angeloni, Alessandro Corsi, Jessica Pepe: no conflict of interest.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}